Author:
Mansoori S.,Fryknäs M.,Alvfors C.,Loskog A.,Larsson R.,Nygren P.
Abstract
AbstractMebendazole is used extensively for treatment of local gut helminthic and invasive echinococcus infections. Anticancer effects of mebendazole have been shown in experimental cancer models and in case studies in patients with advanced cancer. Given these observations, the aims of this study were to investigate safety and efficacy of individualized dosed mebendazole in the cancer indication. Patients with treatment refractory gastrointestinal cancer were treated with individualized dose adjusted mebendazole up to 4 g/day to target a serum concentration of 300 ng/ml. Efficacy and safety were assessed by CT-scans, clinical surveillance and blood sampling. Eleven patients were included in the study and 10 started the treatment phase. Two patients stopped treatment prior to and the remaining eight after tumour evaluation by CT-scan at 8 weeks, all due to progressive disease. Four patients also fulfilled criteria suggested for hyperprogression. Only five patients reached the target serum-mebendazole concentration. No severe adverse effects were observed. Individualized dose adjusted mebendazole is safe and well tolerated in patients with advanced cancer but all patients experienced rapid progressive disease. New approaches such as prodrug development and combination with other anticancer drugs seem needed for further exploration of mebendazole as an anticancer drug.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Witassek, F., Burkhardt, B., Eckert, J. & Bricher, J. Chemotherapy of alveolar echinococcosis. Eur. J. Clin. Pharmacol. 20, 427–433. https://doi.org/10.1007/BF00542095 (1981).
2. Woodtli, W. et al. Effect of plasma mebendazole concentrations in the treatment of human echinococcosis. Am. J. Trop. Med. Hyg. 34, 754–760. https://doi.org/10.4269/ajtmh.1985.34.754 (1985).
3. Luder, P. J., Siffert, B., Witassek, F., Meister, F. & Bricher, J. Treatment of hydatid disease with high oral doses of mebendazol. Eur. J. Clin. Pharmacol. 31, 443–448. https://doi.org/10.1007/BF00613522 (1986).
4. Mukhopadhyay, T., Sasaki, J., Ramesh, R. & Roth, J. A. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin. Cancer. Res. 8, 2963–2969 (2002).
5. Nygren, P., Fryknäs, M., Agerup, B. & Larsson, R. Repositioning of the antihelmintic drug mebendazole for the treatment of colon cancer. J. Cancer. Res. Clin. Oncol. 139, 2133–2140. https://doi.org/10.1007/s00432-013-1539-5 (2013).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献